The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

Access Transportation Research Board Publications Our peer-reviewed reports present the evidence-based consensus of committees of experts. Published proceedings record the presentations and ...

Dotmatics, an early research and development company, says they're using AI to help accelerate the timeline in drug discoveries. "The art of drug discovery is really finding drugs in these massive ...

The president's proposed budget cuts to the NIH would eventually result in fewer drugs on the market, the U.S. Congressional ...

Failure rates remain staggeringly high even with billions of dollars being invested in research and development (R&D). Between 70% and 90% of drug candidates will fail.

Access Transportation Research Board Publications Our peer-reviewed reports present the evidence-based consensus of committees of experts. Published proceedings record the presentations and ...

Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals; 2017 (accessed 19 December 2017). GAO-18-40). Accountability Office.

Rdcthera announced today the release of its revolutionary RDC development services aimed at expediting the bioconjugation drug development process. NEW YORK, NY, USA, July 30, 2024 /EINPresswire ...

Using a novel method to assess spending on research and development for 38 drugs that were recently approved by the U.S. Food and Drug Administration, researchers found that the mean ...

Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

As an important R&D engine of Innovent, Innovent Academy has been deeply exploring and actively deploying AI drug research and development. In this collaboration, Innovent Academy will utilize ...

Research by Andreas Bender at Cambridge University, for example, shows that reducing failures in phase-two trials by just 20% could save nearly $450m on a single drug’s development. In computing ...